Fibromyalgia, Drugs, Cypress Bioscience

Fibromyalgia Drug Delayed

Bruce V. Bigelow 3/8/09

San Diego’s Cypress Bioscience (NASDAQ: CYPB) and New York’s Forest Laboratories (NYSE: FRX) said Friday their launch of a new drug for treating fibromyalgia, which was expected to be available this month, has been delayed by several months. The companies now say they expect to ship the recently approved drug milnacipran HCL (Savella) to wholesalers and pharmacies by mid-2009.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call 858-202-0492